The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 13, Issue 11, Pages 1279-1290
Publisher
Informa UK Limited
Online
2014-09-26
DOI
10.1586/14760584.2014.963561
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The road ahead for cervical cancer prevention and control
- (2014) J.E. Tota et al. Current Oncology
- Development and Implementation of Papillomavirus Prophylactic Vaccines
- (2014) I. H. Frazer JOURNAL OF IMMUNOLOGY
- Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination
- (2013) J. E. Tota et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008-2011
- (2013) L. M. Niccolai et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
- (2013) Mélanie Drolet et al. INTERNATIONAL JOURNAL OF CANCER
- Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes
- (2013) Tom Glass Hopkins et al. VACCINE
- Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England
- (2013) D. Mesher et al. VACCINE
- Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data
- (2013) H. Ali et al. BMJ-British Medical Journal
- HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery
- (2013) Judy Wilyman Infectious Agents and Cancer
- Provinces weighing HPV vaccination of boys
- (2012) L. Eggertson CANADIAN MEDICAL ASSOCIATION JOURNAL
- TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers
- (2012) Kelly Barrios et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Reducing HPV-Associated Cancer Globally
- (2012) D. R. Lowy et al. Cancer Prevention Research
- Prevalence of Cervical Human Papillomavirus (HPV) Infection in Vanuatu
- (2012) B. Aruhuri et al. Cancer Prevention Research
- Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
- (2012) Anne Szarewski Expert Review of Vaccines
- Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
- (2012) S. N. Tabrizi et al. JOURNAL OF INFECTIOUS DISEASES
- Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
- (2012) Nicolas Van de Velde et al. JNCI-Journal of the National Cancer Institute
- Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
- (2012) M. L. Bagarazzi et al. Science Translational Medicine
- Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy
- (2012) Eduardo L. Franco et al. VACCINE
- Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries
- (2012) Karen Canfell et al. VACCINE
- Global Burden of Human Papillomavirus and Related Diseases
- (2012) David Forman et al. VACCINE
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
- (2012) Cecilia M. Roteli-Martins et al. Human Vaccines & Immunotherapeutics
- New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention
- (2011) Elizabeth D Gersch et al. ANTIVIRAL THERAPY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Human papillomavirus: science and technologies for the elimination of cervical cancer
- (2011) F Xavier Bosch EXPERT OPINION ON PHARMACOTHERAPY
- HPV vaccines: what remains to be done?
- (2011) Harald zur Hausen Expert Review of Vaccines
- Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- For Cancers Caused by HPV, Two Vaccines Were Just the Beginning
- (2011) J. Peres JNCI-Journal of the National Cancer Institute
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
- (2011) Julia ML Brotherton et al. LANCET
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
- (2011) Anna R. Giuliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
- (2011) Joel M. Palefsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of recurrent respiratory papillomatosis
- (2010) DANIEL A. LARSON et al. APMIS
- Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological Findings
- (2010) Laia Bruni et al. JOURNAL OF INFECTIOUS DISEASES
- The India HPV-vaccine suspension
- (2010) Heidi J Larson et al. LANCET
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Evaluation of a Cervical Cancer Screening Program Based on HPV Testing and LLETZ Excision in a Low Resource Setting
- (2010) Margaret McAdam et al. PLoS One
- A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
- (2009) Andrea M Anonychuk et al. BMC PUBLIC HEALTH
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
- (2009) S. K. Kjaer et al. Cancer Prevention Research
- Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
- (2009) Barbara A. Slade JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low?
- (2009) Miquel Porta PREVENTIVE MEDICINE
- Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland
- (2009) Kari J. Syrjänen SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis
- (2008) J. Koshiol et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- HPV and cervical cancer: screening or vaccination?
- (2008) F X Bosch et al. BRITISH JOURNAL OF CANCER
- Genital Warts Among 18- to 59-Year-Olds in the United States, National Health and Nutrition Examination Survey, 1999???2004
- (2008) Thu-Ha Dinh et al. SEXUALLY TRANSMITTED DISEASES
- Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions
- (2008) Anna R. Giuliano et al. VACCINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started